are 35,000 new hepatitis C virus (HCV) infections, affecting 1.8% of the population but 6.1% of African Americans. The most effective therapies now are a combination of ribavirin with pegylated interferon. The report stresses that all patients with chronic hepatitis C are potential candidates for antiviral therapy, and it acknowledges that injection drug users and those with comorbid medical and neuropsychiatric conditions should be considered for best current/available treatment. There is a description of the importance of education and syringe access, including syringe-exchange programs and physician prescription of syringes to people who inject drugs. The report also states that "because a large number of HCV infected persons in the United States are incarcerated, programs should be implemented to prevent, diagnose, and treat HCV infection in these individuals." (p19) The report concludes with a dozen recommendations, including the need for screening of incarcerated populations.
COMMENTARY
One third of the nation's estimated 3.9 million HCV-infected individuals pass through a correctional institute in a given year. These people are much more likely to have comorbid conditions of addiction, psychiatric disease, and social problems. The previous consensus statement did not address the incarcerated populations at all and, based on no evidence, recommended excluding persons with active substance abuse. A number of reports have documented that this is inappropriate and underscore the need for diagnosis, treatment, and prevention among persons with substance abuse. The current report appropriately highlights that many of these individuals can be found in the incarcerated setting. Estimates of up to 90% of individuals who inject illicit drugs end up interacting with the criminal justice system. This highlights the importance of the incarcerated setting for the diagnosis, prevention, and treatment of HCV.
Expected this fall is the release of a Centers for Disease Control and Prevention document of over 100 pages that will recommend routine screening of all high-risk inmates for HCV. It will also call for hepatitis B vaccination of all inmates. It is hoped, with the release of these two documents, that more effort will be given to take advantage of public health opportunities in the correctional setting.
Josiah D. Rich

HIV/AIDS Reviews
Miller KD, Masur H, Jones EC, et al. High prevalence of osteonecrosis of the femoral head in HIV-infected adults. Ann Intern Med. 2002; 137:17-24 .
SUMMARY
This survey and comparison study evaluated the prevalence of osteonecrosis of the hip in asymptomatic patients infected with human immunodeficiency virus (HIV). All HIV-infected patients seen in the outpatient clinics of the National Institute of Allergy and Infectious Diseases-National Institutes of Health (NIH) Clinical Center HIV Program from June to December 1999 were recruited for this protocol. Persons with groin or hip pain were excluded. Participants completed a standard questionnaire that elicited joint symptoms, medical history, medication use, and personal habits, including ethanol use, cigarette smoking, and routine exercise regimens. HIV-negative volunteers were recruited from an NIH healthy volunteer database.
Participants included 339 asymptomatic HIV-infected adults (approximately 63% of all patients seen in the clinics during the enrollment period) and 118 age-and sex-matched HIVnegative volunteers. All participants underwent magnetic resonance imaging (MRI) on a 1.5-T MRI system. Positive scans were independently read by two radiologists. Osteonecrosis lesions of the hip were seen in 15 (4.4%; 95% confidence interval [CI] , 2.5% to 7.2%) of the HIV-infected subjects and none of the HIV-negative subjects. Osteonecrosis occurred more often in persons who used corticosteroids, lipid-lowering agents, or testosterone; in persons who routinely practiced bodybuilding; and in persons with detectable levels of anticardiolipin antibodies. Of the 15 patients with osteonecrosis, 10 reported hip discomfort at followup. Protease inhibitor use was high by HIV-infected persons with (93%) and without (92%) osteonecrosis lesions, so no association could be found between antiretroviral use and the prevalence of osteonecrosis.
COMMENTARY
The natural history of HIV infection in developed countries has changed remarkably in the years since 1996, when potent antiretroviral therapy (ART) became routinely available, with the focus shifting from the management of opportunistic infections to the management of toxicities of ART. As HIV infection has developed into a chronic disease and as the duration of effective ART has increased, the incidence of toxicities has increased, and new toxicities have been recognized. Immune reconstitution syndromes, with individuals showing enhanced responses to opportunistic pathogens, are common. Abnormal elevations in lipid profiles require intensive treatment. Dysmorphic changes in body habitus are strongly associated with time on ART. Now, with the increasing longevity associated with the use of potent antiretroviral agents, cases of osteonecrosis have been reported with disturbing frequency.
It will be important to determine whether the increased prevalence of osteonecrosis in this population is associated with specific antiretroviral agents or classes of agents or if it is related to the underlying disease and only becoming manifest now with increasing survival. Although cases of asymptomatic osteonecrosis of the hip have anecdotally progressed to require total hip replacement, it will be important to determine the natural history of this process and to define any interventions that may interrupt its progression. At present, it appears that screening of asymptomatic HIV-infected patients is not warranted, but should be strongly considered in individuals with persistent hip or groin pain.
Oxenius A, Price DA, Gunthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA. 2002; 99:13747-13752 .
SUMMARY
This was an open prospective study designed to evaluate the impact of repeated structured treatment interruptions (STIs) of antiretroviral therapy (ART) on virological and immunological parameters in persons with chronic human immunodeficiency virus type 1 (HIV-1) infection. Eligible subjects were on continuous ART, had plasma HIV viral loads less than 50 copies per milliliter for at least 6 months, and had CD4+ T-cell counts above 300 cells/ mm 3 at enrollment. ART was stopped at enrollment for 2 weeks and resumed for 8 weeks. The cycle was repeated four times. Continuous therapy was resumed if the viral loads remained above 50 copies/mL after retreatment or, if at week 40 the CD4+ T-cell count was less than 400 cells/mm 3 . Alternatively, ART was stopped at week 40 for 3 months and was resumed only for symptoms, viral load above 50,000 copies/mL three times, above 100,000 copies/mL twice, or above 500,000 copies/mL once.
There were 92 men and 41 women enrolled in this Swiss-Spanish intermittent therapy trial. Pretreatment plasma viral loads and off-treatment viral rebound rates were independent predictors of plateau viral loads after STI. Plateau viral loads were slightly lower than pretreatment viral loads, but were unrelated to the magnitude or breadth of the HIV-specific CD8+ T-cell response. Post-STI HIV-specific CD8+ T-cell responses were not enhanced by STI. In summary, STI initiated during this study was unable to significantly alter the individual equilibrium between cellular immunity and viral replication or to significantly lower the viral load.
COMMENTARY
We previously stated that interest in intermittent treatment with highly active antiretroviral therapy (HAART) for HIV infection has been driven by at least four issues: the need to decrease the toxicity of HAART, the need to improve adherence to therapy, the desire to decrease the cost of therapy, and the desire to enhance HIV-specific immune responses ("autovaccination") and improve the host's ability to contain the infection. This is the largest study published to date of STI in individuals with chronic HIV infection.
This study does not address the potential risks of STIs. CD4+ T cell declines and the selection of HIV-1 drug-resistant mutants have anecdotally been reported in association with STI, but the reports are often only available in abstract form. The benefits of antiretroviral therapy are clear. With increasing duration of use, the toxicities of these agents are becoming better defined. To minimize the toxicities of these agents, it is also clear that we must be careful about when and for whom we recommend treatment. In a commentary accompanying the article (Abbas UL, Mellors JW. Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: risk without reward. Proc Natl Acad Sci USA. 2002; 99:13377-13378) , the authors conclude that the autovaccination strategy appears incapable of enhancing immune control of HIV-1 replication in chronic HIV-1 infection. The use of STIs to enhance immune control of HIV-1 replication in chronically infected individuals is an idea that should be discarded; its use in populations to minimize cost and to decrease toxicities of therapy are unresolved issues that should be approached with attention to the known risks carefully weighed against the expected benefits.
Migueles SA, Laborico AC, Shupert WL, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nature Immunol. 2002; 3:1061 -1068 .
SUMMARY
This elegant laboratory study evaluated the CD8+ T-cell response to CD4+ T cells infected with human immunodeficiency virus (HIV) in rare patients with immunological control of HIV and compared the response to that of persons with progressive HIV infection both on and off antiretroviral therapy. Long-term nonprogressors (LTNPs) were strictly defined as the rare patients who consistently had viral concentrations of less than 50 copies/mL, without treatment with antiretroviral agents, and who remained healthy despite chronic HIV infection for up to 20 years.
Fifteen LTNPs were compared to 25 persons with progressive disease both receiving and not receiving antiretroviral therapy (ART). No difference was found between progressors and nonprogressors in the absolute number of HIV-specific CD8+ T cells. Large and rapid expansions of HIV-specific CD8+ T cells in response to HIV-infected autologous CD4+ T cells were seen in the LTNPs, while only a small fraction of HIV-specific CD8+ T cells from progressors divided. This increased proliferative capacity of the cells from nonprogressors was coupled to increased expression of perforin, a protein necessary for killing HIVinfected cells by the granule exocytosis pathway. These results indicated that nonprogressors were distinguished from progressors by increased proliferative capacity of HIV-specific CD8+ T cells linked to enhanced effector function (perforin expression). The relative absence of these functions in progressors may represent a mechanism by which HIV avoids immunological control. These results indicate that the CD8+ T-cell response may be central to control of HIV replication and disease progression.
COMMENTARY
Why some individuals with HIV infection develop a rapidly progressive course soon after infection with high circulating HIV viral loads and rapidly decreasing CD4+ T-cell counts and other individuals maintain high CD4+ T-cell counts with low HIV viral loads (LTNPs) for periods of many years is a question that is an area of active investigation. It is unclear why immunological control of HIV replication is incomplete in most infected individuals. The difficulty in assembling a sufficiently large cohort of these individuals has limited study to date. This study may explain why a small number of HIV-infected persons have no progression of their disease. Specifically, the CD8+ T cells of nonprogressors have a much higher proliferative capacity and enhanced effector function than those of progressors. Understanding the mechanisms involved could lead to the development of new anti-HIV therapies.
This discovery may open areas of investigation in both preventive and therapeutic HIV vaccine research, particularly since most potential vaccines rely on strong cytotoxic CD8+ T-cell responses. Understanding how and why impaired cell cycle dysregulation and decreased perforin expression occurs in persons with progressive HIV infection may ultimately translate into the production of enhanced vaccines.
Michael A. Polis
Child and Adolescent Health Reviews Ribisl K, Kim A, Williams R. Are the sales practices of Internet cigarette vendors good enough to prevent sales to minors? Am J Public Health. 2002; 92:940-941 .
SUMMARY
As part of a larger study on the sales practices of 88 Internet cigarette vendors, the authors collected data from each Web site on minimum age-of-sale warnings and age verification and payment methods. Of the sites, 82% showed one or more age warnings, but only one third included it on the order form. Self-verification of age or a statement of birth date was accepted by almost two thirds of the vendors, with only 6.8% requiring photographic age identification at point of delivery. Credit card payment was accepted by 91%.
COMMENTARY
Here is more evidence that the Internet is not an unmixed blessing when it comes to children's health. According to the National Youth Tobacco Survey, 2000 (reported in MMWR Morb Mortal Wkly Rep. 2001 50(SS-4) :67), 12.6% of middle school and 2.2 % of high school smokers who bought their last pack of cigarettes did so on the Internet. One suspects that cigarette vending is one type of Internet business that will survive the current market vicissitudes, and its usage by adolescents will grow. It seems that the work of tobacco control advocates is never done, and calls will be heard to start campaigning for better regulation of Internet sales to minors. But before mobilizing for this particular battle in the tobacco wars, read on. Fichtenberg C, Glantz S. Youth access interventions do not affect youth smoking. Pediatrics. 2002; 109:1088 -1092 .
SUMMARY
This study consisted of a review of 14 studies, found by a Medline search for the years l985 to 2001, of the effects of youth access laws on teen smoking. Of those studies, 8 were selected for meta-analysis because they either reported both compliance and prevalence data or reported prevalence in intervention and control communities. Compliance was calculated as the percentage of stores visited in a "sting operation" that refused to sell to underage youths. Prevalence was assessed using school-based surveys. Interventions ran the gamut from simple enactment of laws, to retailer and community education, to active enforcement.
When percentage merchant compliance was plotted against youth smoking prevalence, there was no correlation. This lack of correlation held even when change in compliance was measured over time. Similarly, a comparison of intervention and control communities showed no statistically significant differences in youth smoking. In four studies with compliance rates better than 82%, there was no consistent decrease in smoking, a finding that argues against a "threshold effect" by which the level of merchant compliance is effective in controlling purchases and, as a result, reducing smoking.
COMMENTARY
"Enforcement" is one of the nine elements that the Centers for Disease Control and Prevention (CDC) recommends for comprehensive tobacco control programs. But, as this study shows, making it harder for teens to buy cigarettes does not necessarily decrease the prevalence of smoking. The National Youth Tobacco Survey cited above found that only 10% of middle school smokers buy their own cigarettes, and about one third of high school smokers do so. These youngsters describe many other sources of supply. While no one would suggest repeal of the laws forbidding tobacco sales to minors, it is clear that the direct usefulness of major enforcement efforts is not supported by the evidence. The authors argue against even the indirect value of youth access programs, as in promoting community coalitions. They point out that the coalition building may be between the tobacco industry and local merchants. More important, the ever-dwindling tobacco settlement monies still available should be spent on strategies with effectiveness that is proven (i.e., taxes, media campaigns, etc.). In an era that increasingly relies on evidence-based medicine, we also should be expecting evidence-based public health. This kind of article helps fulfill that expectation.
